Journal
CLINICAL INFECTIOUS DISEASES
Volume 57, Issue 9, Pages 1331-1338Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cit539
Keywords
human immunodeficiency virus; herpes simplex virus type 2; valacyclovir; immune activation; randomized controlled trial
Categories
Funding
- Canadian Institutes of Health Research (CIHR)
- CIHR Canadian HIV Trials Network [CTNPT 017]
- Ontario HIV Treatment Network (OHTN)
- CIHR [MOP-115160, 13721, HET-85518]
- OHTN
- Canada Research Chair program
- Skate the Dream Fund
- Toronto Foundation
- Western Hospital Foundation
Ask authors/readers for more resources
Background. Human immunodeficiency virus (HIV) is associated with increased systemic inflammation and immune activation that persist despite suppressive antiretroviral therapy (ART). Herpes simplex virus type 2 (HSV-2) is a common coinfection that may contribute to this inflammation. Methods. Sixty HIV type 1 (HIV-1)/HSV-2-coinfected adults on suppressive ART were randomized 1: 1: 1 to 12 weeks of placebo, low-dose valacyclovir (500 mg twice daily), or high-dose valacyclovir (1 g twice daily) in this 18-week trial. Co-primary outcome measures were the percentage of activated (CD38(+)HLA-DR+) CD8 T cells in blood, and highly sensitive C-reactive protein, interleukin 6, and soluble intercellular adhesion molecule 1 in plasma. Secondary outcomes included additional immune, inflammatory cytokine, and endothelial activation markers. The impact of valacyclovir (both groups combined) on each outcome was estimated using treatment x time interaction terms in generalized estimating equation regression models. Results. Participants were mostly white (75%) men who have sex with men (80%). Median age was 51 (interquartile range [IQR], 47-56) years, median duration of HIV infection was 15 (IQR, 8-21) years, median CD4 count at enrollment was 520 (IQR, 392-719) cells/mu L, and median nadir CD4 count was 142 (IQR, 42-240) cells/mu L. Valacyclovir was not associated with significant changes in any primary or secondary immunological outcomes in bivariate or multivariable models. Medication adherence was 97% by self-report, 96% by pill count, and 84% by urine monitoring. Eight patients had adverse events deemed possibly related to the study drug (5 placebo, 1 low-dose, 2 high-dose), and 6 patients reported at least 1 HSV outbreak (3 placebo, 3 low-dose, 0 high-dose). Conclusions. Valacyclovir did not decrease systemic immune activation or inflammatory biomarkers in HIV-1/HSV-2-coinfected adults on suppressive ART.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available